Skip to main content

Table 1 Clinical data of 8 patients diagnosed as combined hepatocellular-cholangiocarcinoma with stem cell feature

From: Murine hepatoblast-derived liver tumors resembling human combined hepatocellular-cholangiocarcinoma with stem cell features

CaseAge at surgerySexEtiologyLiver fibrosis (Ishak stage 0–6)Serum AFP (µg/L)Serum CA19-9 (µg/L)Tumor location (segments)Tumor numberMaxi tumor diameter (cm)Diagnosis according to WHO criteriaMinor component within intermediated areasPrognosis
150MHBV651.227.2IV, V12CHC with stem cell feature, typical type,Intermediate-cell fociLost follow-up
264MHBV27.6N/AVI, VII110CHC with stem cell feature, intermediate cell typeNoneRecurrence was diagnosed by CT scan in liver at 11 mos. Patient died at 14 mos
349MHBV6 > 1000.00VIII16.5CHC with stem cell feature, intermediate cell typeCholangiolocellular fociRecurrence in liver was diagnosed by CT scan at 13 mos. Patient died soon after recurrence
452MHBV361.20.1V12CHC with stem cell feature, intermediate cell typeFoci with typical type appearanceNone recurrence was found at 74 mos
539MHBV6 > 1000.026.2IV14.5CHC with stem cell feature, intermediate cell typeNoneNew tumor was diagnosed by CT and DSA in liver at 2 mos. patient received TACE, died at 5 mos
655MHBV6561.517.5VI15.3CHC with stem cell feature, intermediate cell typeFoci with typical type appearance and cholangiolocellular fociNew tumor was diagnosed by CT at 42 mos. Patient then received repeat hepatectomy. Resected specimen was pathologically diagnosed as HCC. None recurrence was found at the time of follow-up closure
742MHCV695.139.9II, III, IV39.2CHC with stem cell feature, intermediate cell typeNonePatient died of hemorrhage with no evidence of recurrence at 4 mos
853MHBV6 > 1000.031.8II, III, IV35.5CHC with stem cell feature, intermediate cell typeNoneNew tumor was diagnosed by CT and DSA in liver at 2 mos. After receiving TACE for several times, patient died at 23 mos
  1. AFP alpha-fetoprotein, CA19-9 carbohydrate antigen 19-9, CHC combined hepatocellular-cholangiocarcinoma, CLC cholangiolocarcinoma, CT computed tomography, HBV hepatitis B virus, HCV hepatitis C virus, DSA digital subtraction angiography, HCC hepatocellular carcinoma, TACE transarterial chemoembolization, WHO World Health Organization